ASPHALION is participating in the 23rd ASGCT herapy Annual Meeting organized by the American Society of Gene & Cell Therapy.
As international SME Drug Development and Regulatory Affairs Consultancy, we have broad experience dealing with ATMPs and Biologics giving strategic regulatory and scientific advice in preclinical, clinical or CMC aspects from early development to clinical stages and MA procedures. We have experience in different products such as CAR-T cells, autologous and allogenic expanded stem cells, mesenchymal stem cells, oncolytic virus, AAV, plasmids, among others.
Our consultants are experts in their field and are in direct contact with FDA and EU agencies for the development and implementation of new regulatory standards.
Lidia Cánovas, Oriol Penon and Christopher Mann will be fully available during this meeting to answer your questions and doubts.
#ASGCT20 #genetherapy
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del...
Theriva™ Biologics has announced the presentation of preclinical da...
